Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Citius Pharmaceuticals, Inc.CTXR · Entity 7778 | Director | October 04, 2022 | October 06, 2022 |
| VERINT SYSTEMS INCVRNT · Entity 72443 | Director | April 20, 2021 | April 22, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Citius Pharmaceuticals, Inc.
Report date October 04, 2022 · Filed October 06, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.25 · Expires 2032-10-04 | Direct | 75,000 |
Reported balance
After 2022-10-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-10-04 · Grant · Acquired 75,000 · Balance 75,000 F1: The options were granted on October 4, 2022. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. |
| Options to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.04 · Expires 2031-10-11 | Direct | 75,000 |
Reported balance
Holding disclosure · report date 2022-10-04 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 75,000 F2: The options were granted on October 11, 2021. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. |
| Options to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2031-07-22 | Direct | 15,000 |
Reported balance
Holding disclosure · report date 2022-10-04 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 15,000 F3: The options vested in full on July 22, 2022. |
| Options to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.69 · Expires 2031-02-16 | Direct | 25,000 |
Reported balance
Holding disclosure · report date 2022-10-04 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 25,000 F4: The options vested in full on February 16, 2022. |
| Options to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.01 · Expires 2030-10-06 | Direct | 35,000 |
Reported balance
Holding disclosure · report date 2022-10-04 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 35,000 F5: The options vested in full on October 6, 2021. |
| Options to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2030-07-07 | Direct | 25,000 |
Reported balance
Holding disclosure · report date 2022-10-04 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 25,000 F6: The options vested in full on July 7, 2021. |
| Options to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.67 · Expires 2029-10-08 | Direct | 25,000 |
Reported balance
Holding disclosure · report date 2022-10-04 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 25,000 F7: The options vested in full on October 8, 2020. |
| Options to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.62 · Expires 2028-09-04 | Direct | 15,000 |
Reported balance
Holding disclosure · report date 2022-10-04 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 15,000 F8: The options vested in full on September 4, 2019. |
| Options to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2027-09-13 | Direct | 10,000 |
Reported balance
Holding disclosure · report date 2022-10-04 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 10,000 F9: The options vested in full on September 13, 2018. |
| Options to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.02 · Expires 2024-04-11 | Direct | 12,071 |
Reported balance
Holding disclosure · report date 2022-10-04 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 12,071 F10: The options vested in 1/3 increments over a three-year period with the first installment vesting on April 11, 2015. |
| Options to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2026-06-23 | Direct | 13,334 |
Reported balance
Holding disclosure · report date 2022-10-04 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 13,334 F11: The options vested in full on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on October 4, 2022. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date.
F2: The options were granted on October 11, 2021. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date.
F3: The options vested in full on July 22, 2022.
F4: The options vested in full on February 16, 2022.
F5: The options vested in full on October 6, 2021.
F6: The options vested in full on July 7, 2021.
F7: The options vested in full on October 8, 2020.
F8: The options vested in full on September 4, 2019.
F9: The options vested in full on September 13, 2018.
F10: The options vested in 1/3 increments over a three-year period with the first installment vesting on April 11, 2015.
F11: The options vested in full on the first anniversary of the date of grant.
VERINT SYSTEMS INC
Report date April 20, 2021 · Filed April 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,838 |
Reported balance
After 2021-04-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-04-20 · Grant · Acquired 4,178 · Balance 30,838 F1: Grant of restricted stock units vesting 100% on April 11, 2022. F2: The number of shares underlying unvested RSUs that were previously reported on Form 4 has been adjusted in connection with the closing of the spin-off of Cognyte Software Ltd. by the Issuer on February 1, 2021 and included in the total in Column 5. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units vesting 100% on April 11, 2022.
F2: The number of shares underlying unvested RSUs that were previously reported on Form 4 has been adjusted in connection with the closing of the spin-off of Cognyte Software Ltd. by the Issuer on February 1, 2021 and included in the total in Column 5.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 04, 2022 Filed Oct 6, 2022 16:07 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 75,000 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001213900-22-062478 · ownership.xml · derivative · entry 1 SAFIR HOWARD · CIK 0001221559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-10-04 F1 · security: The options were granted on October 4, 2022. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. F1 · derivative.exercise_date: The options were granted on October 4, 2022. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. Read SEC document |
| October 11, 2021 Filed Oct 13, 2021 17:25 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 75,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001213900-21-052672 · ownership.xml · derivative · entry 1 SAFIR HOWARD · CIK 0001221559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-10-11 F1 · security: The options were granted on October 11, 2021. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. F1 · derivative.exercise_date: The options were granted on October 11, 2021. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date. Read SEC document |
| July 22, 2021 Filed Jul 26, 2021 17:01 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 15,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001213900-21-038693 · ownership.xml · derivative · entry 1 SAFIR HOWARD · CIK 0001221559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-07-22 F1 · security: The options vest in full on July 22, 2022. F1 · derivative.exercise_date: The options vest in full on July 22, 2022. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 17:18 UTC | VERINT SYSTEMS INC VRNT · Entity 72443 | GrantCommon Stock | 4,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001166388-21-000070 · wf-form4_161912626985097.xml · nonDerivative · entry 1 SAFIR HOWARD · CIK 0001221559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,838 F1 · shares: Grant of restricted stock units vesting 100% on April 11, 2022. F2 · balance_after: The number of shares underlying unvested RSUs that were previously reported on Form 4 has been adjusted in connection with the closing of the spin-off of Cognyte Software Ltd. by the Issuer on February 1, 2021 and included in the total in Column 5. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 16:08 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 25,000 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001213900-21-010319 · ownership.xml · derivative · entry 1 SAFIR HOWARD · CIK 0001221559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-02-16 F1 · security: The options vest in full on February 16, 2022. F1 · derivative.exercise_date: The options vest in full on February 16, 2022. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 17:08 UTC | VERINT SYSTEMS INC VRNT · Entity 72443 | SaleCommon Stock | 8,333 | $60.21 | $501,729.93 |
DisclosureSEC source: 0001166388-20-000159 · wf-form4_160815646937778.xml · nonDerivative · entry 1 SAFIR HOWARD · CIK 0001221559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,693 F1 · price: Represents the weighted average price for sales of the shares. The shares were sold at prices ranging from $60.02 per share to $60.47 per share. F2 · price: The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 06, 2020 Filed Oct 9, 2020 16:06 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 35,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001213900-20-030791 · ownership.xml · derivative · entry 1 SAFIR HOWARD · CIK 0001221559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-10-06 F1 · security: The options vest in full on October 6, 2021. F1 · derivative.exercise_date: The options vest in full on October 6, 2021. Read SEC document |
| August 26, 2020 Filed Aug 28, 2020 16:53 UTC | VERINT SYSTEMS INC VRNT · Entity 72443 | GrantCommon Stock | 4,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001166388-20-000104 · wf-form4_159864800842594.xml · nonDerivative · entry 1 SAFIR HOWARD · CIK 0001221559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,026 F1 · shares: Grant of restricted stock units vesting 100% on April 8, 2021. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 16:05 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 25,000 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001213900-20-017075 · ownership.xml · derivative · entry 1 SAFIR HOWARD · CIK 0001221559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-07-07 F1 · security: The options vest in full on July 7, 2021. F1 · derivative.exercise_date: The options vest in full on July 7, 2021. Read SEC document |
| October 08, 2019 Filed Oct 10, 2019 16:15 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 25,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001213900-19-020124 · ownership.xml · derivative · entry 1 SAFIR HOWARD · CIK 0001221559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-10-08 F1 · security: The options vest in full on October 8, 2020. F1 · derivative.exercise_date: The options vest in full on October 8, 2020. Read SEC document |
| April 19, 2019 Filed Apr 23, 2019 16:50 UTC | VERINT SYSTEMS INC VRNT · Entity 72443 | GrantCommon Stock | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001166388-19-000068 · wf-form4_155605259130956.xml · nonDerivative · entry 1 SAFIR HOWARD · CIK 0001221559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,700 F1 · shares: Grant of restricted stock units vesting 100% on April 6, 2020. Read SEC document |
| April 09, 2019 Filed Apr 11, 2019 17:24 UTC | VERINT SYSTEMS INC VRNT · Entity 72443 | Tax withholdingCommon Stock | 1,910 | $62.04 | $118,496.40 |
DisclosureSEC source: 0001166388-19-000037 · wf-form4_155501784244687.xml · nonDerivative · entry 1 SAFIR HOWARD · CIK 0001221559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,400 F1 · shares: Shares withheld by the Company pursuant to the reporting person's award agreement in order to facilitate tax payments by the reporting person resulting from the vesting of a previously disclosed award. Read SEC document |
| September 10, 2018 Filed Sep 11, 2018 16:07 UTC | VERINT SYSTEMS INC VRNT · Entity 72443 | SaleCommon Stock | 4,000 | $50.07 | $200,280.00 |
DisclosureSEC source: 0001166388-18-000095 · wf-form4_153669645572537.xml · nonDerivative · entry 1 SAFIR HOWARD · CIK 0001221559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,310 Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 16:16 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 15,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001213900-18-012201 · ownership.xml · derivative · entry 1 SAFIR HOWARD · CIK 0001221559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-09-04 F1 · security: The options vest in full on the first anniversary of the vesting commencement date, September 4, 2019. F1 · derivative.exercise_date: The options vest in full on the first anniversary of the vesting commencement date, September 4, 2019. Read SEC document |
| April 20, 2018 Filed Apr 23, 2018 17:27 UTC | VERINT SYSTEMS INC VRNT · Entity 72443 | GrantCommon Stock | 4,773 | $0.00 | $0.00 |
DisclosureSEC source: 0001166388-18-000051 · wf-form4_152451883165689.xml · nonDerivative · entry 1 SAFIR HOWARD · CIK 0001221559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,310 F1 · shares: Grant of restricted stock units vesting 100% on April 9, 2019. Read SEC document |
| April 20, 2017 Filed Apr 24, 2017 16:39 UTC | VERINT SYSTEMS INC VRNT · Entity 72443 | GrantCommon Stock | 5,076 | $0.00 | $0.00 |
DisclosureSEC source: 0001166388-17-000063 · wf-form4_149306637527517.xml · nonDerivative · entry 1 SAFIR HOWARD · CIK 0001221559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,537 F1 · shares: Grant of restricted stock units vesting 100% on April 12, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.